ProCE Banner Activity

Interim Analysis of Phase II PURE-01 Trial: Neoadjuvant Pembrolizumab in Patients With Muscle-Invasive Urothelial Bladder Carcinoma

Slideset Download
Conference Coverage
Neoadjuvant pembrolizumab associated with a pathologic CR rate of 39.5% and no surgical delay in MIBC patients scheduled for radical cystectomy.

Released: June 12, 2018

Expiration: June 11, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen